Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference
Genocea Biosciences (NASDAQ: GNCA) will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. Chip Clark, CEO, will lead the presentation, with a webcast available on their investor website starting January 11. Post-conference, the presentation will be archived for approximately 90 days. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform to identify neoantigens that optimize immune responses against tumors. To learn more, visit their website.
- None.
- None.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference being held from January 11 – 14, 2021. A webcast of the on-demand presentation will be available on the investor section of the Genocea website at http://ir.genocea.com, beginning on Monday, January 11, 2021.
Following the conclusion of the conference, the presentation will remain archived on the Genocea website for approximately 90 days.
About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit www.genocea.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.
Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com
FAQ
When will Genocea Biosciences present at the H.C. Wainwright Virtual BioConnect Conference?
Who will present for Genocea at the conference?
Where can I watch the Genocea presentation?
How long will the Genocea presentation be available after the conference?
What is the focus of Genocea Biosciences' development?
